| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.06 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.088 | 0.06 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.067 | 0.06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.085 | 0.06 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.066 | 0.06 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.06 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.058 | 0.06 |